[Report] Antifungal Agents Market Research Trends, Analysis TOC

INTRODUCTION
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THIS STUDY
- CONTRIBUTIONS TO THE STUDY AND FOR WHOM
- SCOPE AND FORMAT
- METHODOLOGY
- INFORMATION SOURCES
- ANALYST CREDENTIALS
- RELATED BCC REPORTS
- DISCLAIMER
SUMMARY
- Summary Table:
- GLOBAL MARKET FORECAST FOR ANTIFUNGAL AGENTS, THROUGH 2012 ($ MILLIONS)
- Summary Figure:
- GLOBAL ANTIFUNGAL AGENT SALES BY MARKET SEGMENT, 2005 AND 2012 (%)
OVERVIEW
- HISTORY AND CURRENT STATE OF ANTIMICROBIALS
- Table 1 DEATHS ATTRIBUTABLE TO MICROBIOLOGIC PATHOGENS IN HISTORY
  - TYPES OF ANTIMICROBIALS
    - BACTERIA
    - VIRUSES
    - PROTOZOA
    - FUNGI
  - DEFINITION OF THE INDUSTRY
  - CONCEPTS IN THE INDUSTRY
  - IMPORTANCE OF THE INDUSTRY
  - PRODUCT LIFE CYCLES
- Table 2 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG
  - DEVELOPMENT OF ANTIFUNGALS
  - FUTURE DEVELOPMENTS
    - 2006 NEW DRUG ACTIVITY
    - 2005 NEW DRUG ACTIVITY
  - WITH AN EYE TOWARD THE FUTURE
TYPE OF APPLICATIONS: HUMAN HEALTHCARE, VETERINARY, AGRICULTURE, AND ENVIRONMENTAL
- TYPE OF APPLICATIONS: HUMAN HEALTHCARE
- HUMAN FUNGAL INFECTIONS
  - RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS
- Table 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
  - CANDIDIASIS
    - Cutaneous Candidiasis
    - Chronic Mucocutaneous Candidiasis
    - GI Tract Candidiasis
    - Respiratory Tract Candidiasis
    - Genitourinary Tract Candidiasis
    - Hepatosplenic Candidiasis
    - Systemic Candidiasis
      - Candidemia
      - Disseminated Candidiasis
  - ASPERGILLOSIS
  - BLASTOMYCOSIS
  - COCCIDIOIDOMYCOSIS
  - CRYPTOCOCCOSIS
  - DERMATOPHYTOSIS
  - HISTOPLASMOSIS
  - ONYCHOMYCOSIS
  - PARACOCCIDIOIDOMYCOSIS
  - PSEUDALLESCHERIASIS
  - SPOROTRICHOSIS
  - ZYGOMYCOSIS
- Table 4 INCIDENCE OF COMMON FUNGAL DISEASES
  - HUMAN ANTIFUNGAL AGENTS
- Table 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2012 ($ MILLIONS)
  - ECHINOCANDINS
  - ANTIMETABOLITES
  - AZOLES
  - POLYENES
  - OTHER
- Table 6 ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS THROUGH 2009 ($ MILLIONS)
- Table 7 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Figure 1 PERCENTAGE ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Table 8 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE
- Table 9 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
- Table 10 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT
  - SIDE EFFECTS
- Table 11 LIFE THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS
  - OVER THE COUNTER ANTIFUNGAL PREPARATIONS
- Table 12 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION
  - NATURAL ANTIFUNGAL COMPLEXES
    - Herbal Antifungal Agents
- Table 13 COMMON HERBAL ANTIFUNGALS
  - Enzyme-Based Antifungal Agents
- Table 14 COMMON ENZYMES USED IN NATURAL ANTIFUNGAL PRODUCTS
  - Homeopathic Antifungal Agents
- LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS
  - SPECIMEN EXAMINATION
  - CULTURES
  - BLOOD SEROLOGY
- ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS
  - CAM TESTING AND SPECIALIZED LABORATORIES
  - QUESTIONNAIRE FOR SYMPTOMS
    - FUNGAL RESISTANCE
- Table 15 COMMON REASONS FOR FUNGAL RESISTANCE
  - STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY
VETERINARY ANTIFUNGAL SEGMENT
- THE INDUSTRY
- VETERINARY FUNGAL INFECTIONS
  - ASPERGILLOSIS
  - CANDIDIASIS
  - COCCIDIOIDOMYCOSIS
  - CRYPTOCOCCOCOSIS
  - EPIZOOTIC LYMPHANGITIS UNIQUE TO HORSES
  - GEOTRICHOSIS
  - HISTOPLASMOSIS
  - HYALOHYPHOMYCOSIS
  - MYCETOMAS
  - NORTH AMERICAN BLASTOMYCOSIS
  - OOMYCOSIS
  - PAECILOMYCOSIS
  - PENNICILLIOSIS
  - PHAEOHYPHOMYCOSIS
  - RHINOSPORIDIOSIS
  - SPOROTRICHOSIS
  - ZYGOMYCOSIS
- VETERINARY ANTIFUNGAL AGENTS
  - POLYENES
  - AZOLES
  - ANTIMETABOLITES
  - OTHER
    - Griseofulvin
    - Lufenuron
- Table 16 VETERINARY FUNGAL INFECTIONS AND PHARMACEUTICAL OPTIONS
- Table 16 (CONTINUED)
- Table 17 COMMON SIDE EFFECTS FROM VETERINARY ANTIFUNGALS
  - VETERINARY BASED LABORATORY TESTS AND HISTOLOGY
AGRICULTURAL ANTIFUNGAL SEGMENT
- THE INDUSTRY
- GOVERNMENT REGULATIONS
  - AGRICULTURE ANTIFUNGALS: MECHANISMS OF ACTION
  - AGRICULTURAL PRODUCTS AND APPLICATIONS
- Table 18 AGRICULTURAL ANTIFUNGAL ACTIVE INGREDIENTS WITH =100,000 LBS APPLIED, 2002
- Table 18 (CONTINUED)
- Table 19 ANTIFUNGAL USE BY REGION OF THE UNITED STATES, 2002
- Table 20 ANTIFUNGAL USE BY CROP TYPE, 2002
  - AGRICULTURAL SIDE EFFECTS
- Table 21 SIDE EFFECTS FROM COMMON AGRICULTURAL ANTIFUNGAL AGENTS
- Table 21 (CONTINUED)
  - AGRICULTURAL FUNGAL RESISTANCE
  - STRATEGIES TO PREVENT FUNGAL RESISTANCE IN AGRICULTURAL FUNGI
ENVIRONMENTAL ANTIFUNGAL SEGMENT
- THE INDUSTRY
- WHY ENVIRONMENTAL MOULD IS A UNIQUE PROBLEM
- COMMON ENVIRONMENTAL MOULDS
  - ALTERNARIA
  - ASPERGILLUS
  - CLADOSPORIUM
  - PENICILLIUM
    - HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOULD
- Table 22 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOULDS
- Table 23 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOULD REACTIONS
- Table 24 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOULDS
GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS
- GOVERNMENT REGULATIONS
  - FOOD AND DRUG ADMINISTRATION
- Table 25 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA 1997-2006
- Table 25 (CONTINUED)
  - ENVIRONMENTAL PROTECTION AGENCY (EPA)
  - UNITED STATED DEPARTMENT OF AGRICULTURE (USDA)
  - FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS
- PROFESSIONAL ASSOCIATIONS
  - MEDICAL AND VETERINARY ASSOCIATIONS
  - AGRICULTURAL ASSOCIATIONS
  - OTHER ENVIRONMENTAL ASSOCIATIONS
MAJOR ANTIFUNGAL MANUFACTURERS
- HUMAN HEALTHCARE
  - PHARMACEUTICAL MANUFACTURERS
- Table 26 MAJOR ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS
- Table 26 (CONTINUED)
- Figure 2 PERCENTAGE OF ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY
- Table 27 MAJOR PHARMACEUTICAL ANTIFUNGAL MANUFACTURERS, 2006 ($ MILLION)
  - MAJOR PHARMACEUTICAL MANUFACTURER PROFILES
    - Astellas
    - Barrier Therapeutics
    - Enzon Pharmaceuticals
    - Gilead Sciences, Inc.
    - Medicis
    - Teva Pharmaceutical USA
    - Novartis
    - Pfizer, Inc.
    - Schering-Plough Corp.
    - SciClone Pharmaceuticals, Inc.
    - Taro Pharmaceutical Industries, Ltd.
    - York Pharma
  - MAJOR OTC ANTIFUNGAL MANUFACTURERS
    - PHARMACEUTICAL OTC MARKET
- Table 28 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
  - PHARMACEUTICAL-BASED OTC MANUFACTURER PROFILES
    - Alva-Amco Pharmacal
    - Blaine Labs
    - Dartmouth Pharmaceuticals
    - Del Laboratories
    - Dermik
    - Ganeden Biotech
    - McNeil Consumer and Specialty Pharmaceuticals
    - Kramer Laboratories
    - Novartis
    - Pedinol Pharmacal
    - Pfizer
    - Schering-Plough
    - Stiefel Laboratories
    - Tarmac Products
  - ALTERNATIVE OTC MARKET
- Table 29 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS
  - ProSymbiotics
  - Nature' s Plus
  - Aqua Flora
  - NOW Foods
  - Rainbow Light
  - Enzymedica
  - Pure Essence Laboratories
  - Michael' s Naturopathic Programs
  - Renew Life
  - Garden of Life
  - Nutrition Now
  - Solaray
  - Vitanica
  - Forest Herbs Research
  - Crystal Star Herbal Nutrition
- VETERINARY MARKET
- Table 30 MAJOR VETERINARY ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS AND PRODUCTS
- Table 30 (CONTINUED)
- Figure 3 PERCENTAGE OF MANUFACTURERS OF VETERINARY ANTIFUNGALS BY COUNTRY (%)
  - MAJOR VETERINARY ANTIFUNGAL MANUFACTURER PROFILES
    - Argent
    - Bioniche Life Science
    - Butler Animal Health
    - Durvet Animal Health Products
    - Med-Pharmex
    - Virbac
    - Schering-Plough Animal Health
    - Stiefel
    - Vetoquinol
    - Vedco
    - Wyeth Animal Health
  - AGRICULTURAL ANTIFUNGAL MANUFACTURERS
- Table 31 MAJOR AGRICULTURAL ANTIFUNGAL MANUFACTURERS
- Figure 4 PERCENT AGRICULTURAL ANTIFUNGAL MANUFACTURERS BY COUNTRY (%)
  - MAJOR AGRICULTURAL MANUFACTURER PROFILES
    - AgriChem
    - AgraQuest
    - Albaugh, Inc.
    - American Vanguard
    - Arysta Life Sciences
    - BASF
    - Bayer CropScience
    - Makhteshim Agan of North America, Inc.
    - Cerexagri
    - Chemtura
    - Dow AgroSciences
    - DuPont Crop Protection
    - Gowan
    - JH Biotech
    - Helena Chemical Company
    - Nordox AS
    - Nufarm
    - Syngenta
    - Valent
ANTIFUNGAL INDUSTRY
- ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE
  - ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT
- Table 32 PHARMACEUTICAL ANTIFUNGAL PRODUCTS IN THE PIPELINE, 2006
- Table 33 NEW PRESCRIPTION ANTIFUNGALS, 2005-2006
  - INCREASED TYPES OF TESTING
    - Need to Increase Use and Acceptance of Newer Drugs
    - Trends in Class Used and Administration Method
- Table 34 PHARMACEUTICAL ANTIFUNGALS BY ADMINISTRATION TYPE (%)
- Figure 5 PERCENTAGE OF PHARMACEUTICAL ANTIFUNGAL PRODUCTS BY ADMINISTRATION TYPE (%)
- Table 35 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ADMINISTRATION, THROUGH 2012 ($ MILLIONS)
  - UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS
    - Shifting Market from Prescription to OTC
- Table 36 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS
- Table 37 SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 ($ MILLIONS)
  - Market Demand for OTC Products
- ANTIFUNGAL MARKET TRENDS: VETERINARY HEALTH
- ANTIFUNGAL MARKET TRENDS-AGRICULTURAL
  - DECREASE IN NUMBER OF MANUFACTURERS
  - DECREASE IN PRICE PER POUND OF SYNTHETIC AGENTS
  - INCREASED PRODUCTION AND DISTRIBUTION OF GENERICS
  - INCREASE IN FUNGAL RESISTANCE IN PHYTOMYCOTIC ORGANISMS
PATENT ANALYSIS
- PURPOSE OF A PATENT ANALYSIS
- DUE CARE IN REVIEWING THE PATENT ANALYSIS
  - NEW ANTIFUNGAL PATENTS ISSUED
- Table 38 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Table 38 (CONTINUED)
- Figure 6 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Table 39 PATENT BY ANTIFUNGAL MARKET SEGMENT, 1990-2006
- Table 40 NEW ANTIFUNGAL PATENTS ISSUED, 2005-2006
- Table 40 (CONTINUED)
- Table 40 (CONTINUED)
- Table 40 (CONTINUED)
- Table 41 ASSIGNEES OF THREE OR MORE PATENTS FOR ANTIFUNGAL PRODUCTS, 2005-2006
- Table 42 PATENT TRENDS BY COUNTRY, 2005-2006
- Figure 7 NEW ANTIFUNGAL PATENT APPROVALS BY COUNTRY, 2005-2006 (%)
  - TRENDS IN PATENT APPLICATIONS
- Table 43 PATENT APPLICATION TRENDS, 2001-2006
- Figure 8 ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2001-2006 (%)
- Table 44 PATENT APPLICATIONS BY ANTIFUNGAL SEGMENT, 2001-2006
- Figure 9 PERCENTAGE OF PATENT APPLICATIONS BY ANTIFUNGAL MARKET SEGMENT, 2001-2006 (%)
- Table 45 NEW PATENT APPLICATIONS, 2005-2006
- Table 45 (CONTINUED)
- Table 45 (CONTINUED)
- Table 46 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MARKET SEGMENT, 2005-2006
- Table 47 PATENT APPLICATION TRENDS BY COUNTRY, 2005-2006
- Figure 10 ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2005-2006 (%)
  - PATENT EXPIRATIONS
- Table 48 PATENT EXPIRATIONS, 2006-2011
APPENDIX
- Table 49 PHARMACEUTICAL COMPANIES
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
LIST OF TABLES
- Summary Table:
- GLOBAL MARKET FORECAST FOR ANTIFUNGAL AGENTS, THROUGH 2012 ($ MILLIONS)
- Table 1 DEATHS ATTRIBUTABLE TO MICROBIOLOGIC PATHOGENS IN HISTORY
- Table 2 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG
- Table 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
- Table 4 INCIDENCE OF COMMON FUNGAL DISEASES
- Table 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2012 ($ MILLIONS)
- Table 6 ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS THROUGH 2009 ($ MILLIONS)
- Table 7 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Table 8 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE
- Table 9 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
- Table 10 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT
- Table 11 LIFE THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS
- Table 12 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION
- Table 13 COMMON HERBAL ANTIFUNGALS
- Table 14 COMMON ENZYMES USED IN NATURAL ANTIFUNGAL PRODUCTS
- Table 15 COMMON REASONS FOR FUNGAL RESISTANCE
- Table 16 VETERINARY FUNGAL INFECTIONS AND PHARMACEUTICAL OPTIONS
- Table 17 COMMON SIDE EFFECTS FROM VETERINARY ANTIFUNGALS
- Table 18 AGRICULTURAL ANTIFUNGAL ACTIVE INGREDIENTS WITH =100,000 LBS APPLIED, 2002
- Table 19 ANTIFUNGAL USE BY REGION OF THE UNITED STATES, 2002
- Table 20 ANTIFUNGAL USE BY CROP TYPE, 2002
- Table 21 SIDE EFFECTS FROM COMMON AGRICULTURAL ANTIFUNGAL AGENTS
- Table 22 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOULDS
- Table 23 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOULD REACTIONS
- Table 24 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOULDS
- Table 25 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA 1997-2006
- Table 26 MAJOR ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS
- Table 27 MAJOR PHARMACEUTICAL ANTIFUNGAL MANUFACTURERS, 2006($ MILLION)
- Table 28 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
- Table 29 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS
- Table 30 MAJOR VETERINARY ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS AND PRODUCTS
- Table 31 MAJOR AGRICULTURAL ANTIFUNGAL MANUFACTURERS
- Table 32 PHARMACEUTICAL ANTIFUNGAL PRODUCTS IN THE PIPELINE, 2006
- Table 33 NEW PRESCRIPTION ANTIFUNGALS2005-2006
- Table 34 PHARMACEUTICAL ANTIFUNGALS BY ADMINISTRATION TYPE (%)
- Table 35 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ADMINISTRATION, THROUGH 2012 ($ MILLIONS)
- Table 36 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS
- Table 37 SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 ($ MILLIONS)
- Table 38 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Table 39 PATENT BY ANTIFUNGAL MARKET SEGMENT1990-2006
- Table 40 NEW ANTIFUNGAL PATENTS ISSUED, 2005-2006
- Table 41 ASSIGNEES OF THREE OR MORE PATENTS FOR ANTIFUNGAL PRODUCTS, 2005-2006
- Table 42 PATENT TRENDS BY COUNTRY, 2005-2006
- Table 43 PATENT APPLICATION TRENDS, 2001-2006
- Table 44 PATENT APPLICATIONS BY ANTIFUNGAL SEGMENT, 2001-2006
- Table 45 NEW PATENT APPLICATIONS, 2005-2006
- Table 46 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MARKET SEGMENT, 2005-2006
- Table 47 PATENT APPLICATION TRENDS BY COUNTRY, 2005-2006
- Table 48 PATENT EXPIRATIONS, 2006-2011
- Table 49 PHARMACEUTICAL COMPANIES
LIST OF FIGURES
- Summary Figure:
- GLOBAL ANTIFUNGAL AGENT SALES BY MARKET SEGMENT, 2005 AND 2012 (%)
- Figure 1 PERCENTAGE ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Figure 2 PERCENTAGE OF ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY
- Figure 3 PERCENTAGE OF MANUFACTURERS OF VETERINARY ANTIFUNGALS BY COUNTRY (%)
- Figure 4 PERCENT AGRICULTURAL ANTIFUNGAL MANUFACTURERS BY COUNTRY (%)
- Figure 5 PERCENTAGE OF PHARMACEUTICAL ANTIFUNGAL PRODUCTS BY ADMINISTRATION TYPE (%)
- Figure 6 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Figure 7 NEW ANTIFUNGAL PATENT APPROVALS BY COUNTRY, 2005-2006 (%)
- Figure 8 ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2001-2006 (%)
- Figure 9 PERCENTAGE OF PATENT APPLICATIONS BY ANTIFUNGAL MARKET SEGMENT, 2001-2006 (%)
- Figure 10 ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2005-2006 (%)

Global Markets for Antifungal Agents

Table of Contents